Complete Atrioventricular Block Secondary to Bortezomib Use in Multiple Myeloma

Bortezomib is an inhibitor of 26S proteasome, which is an effective treatment for multiple myeloma. The common adverse effects of bortezomib are asthenic conditions, gastrointestinal disturbances, and peripheral neuropathy. Here we describe a patient with dyspnea and general weakness because of comp...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Won-Seop, Kim, Dae-Hyeok, Shin, Sung-Hee, Woo, Seoung-Il, Kwan, Jun, Park, Keum-Soo, Park, Sang-Don, Yi, Hyeon-Gyu, Jeon, Sang-Hoon
Formato: Texto
Lenguaje:English
Publicado: Yonsei University College of Medicine 2011
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3017698/
https://www.ncbi.nlm.nih.gov/pubmed/21155055
http://dx.doi.org/10.3349/ymj.2011.52.1.196
Descripción
Sumario:Bortezomib is an inhibitor of 26S proteasome, which is an effective treatment for multiple myeloma. The common adverse effects of bortezomib are asthenic conditions, gastrointestinal disturbances, and peripheral neuropathy. Here we describe a patient with dyspnea and general weakness because of complete atrioventricular block while receiving bortezomib. We immediately stopped bortezomib, and after inserting a permanent VDD pacemaker, the patients' symptoms disappeared.

Ejemplares similares